AIM: To assess the major determinants of glucose tolerance between age, genotype, and clinical status in cystic fibrosis (CF) patients, and study if defects of insulin secretion and insulin sensitivity were associated with the onset of CF-related diabetes (CFRD). SUBJECTS AND METHODS: One hundred and nineteen patients, in stable clinical condition were studied. They were subdivided into 3 groups based on age, and 2 groups based on Schwachman-Kulczycki clinical score. All patients were genotyped, and subsequently divided into 3 groups. Ninety-four healthy normal-weight controls, comparable for sex and age were also studied. All subjects had baseline blood samples taken for glucose and insulin, C-peptide, and glycated hemoglobin. Homeostasis model assessment of insulin resistance (HOMA-IR), fasting glucose/insulin ratio (FGIR) were calculated as indices of IR and insulinogenic index as a marker of pancreatic β-cell function. All patients underwent an oral glucose tolerance test, and 57 underwent an IVGTT for the calculation of first-phase (FPIR) and acute insulin responses (AIR). RESULTS: The F508del homozygous patients had an increased chance of developing impaired glucose tolerance (IGT) and significantly lower FPIR, decreased HOMA-IR, and insulinogenic index. Heterozygote F508del patients had an increased chance of having normal glucose tolerance. HOMA-IR, FGIR, and insulinogenic index did not change with age or clinical score. HOMAIR correlated with FPIR. FPIR correlated positively with insulinogenic index. AIR correlated negatively with FGIR, and positively with C-reactive protein. In multiple linear regression analyses, glucose tolerance was related to the agegroup, and to the HOMA-IR and insulinogenic indexes. CONCLUSIONS: IGT and CFRD were related mainly to genotype, although, as expected, the prevalence increased with age. The data suggested a possible combined contribution of insulin deficiency, β-cell function, and reduced insulin sensitivity to the onset of CFRD; however, further studies are warranted to better elucidate this aspect.
AIM: To assess the major determinants of glucose tolerance between age, genotype, and clinical status in cystic fibrosis (CF) patients, and study if defects of insulin secretion and insulin sensitivity were associated with the onset of CF-related diabetes (CFRD). SUBJECTS AND METHODS: One hundred and nineteen patients, in stable clinical condition were studied. They were subdivided into 3 groups based on age, and 2 groups based on Schwachman-Kulczycki clinical score. All patients were genotyped, and subsequently divided into 3 groups. Ninety-four healthy normal-weight controls, comparable for sex and age were also studied. All subjects had baseline blood samples taken for glucose and insulin, C-peptide, and glycated hemoglobin. Homeostasis model assessment of insulin resistance (HOMA-IR), fasting glucose/insulin ratio (FGIR) were calculated as indices of IR and insulinogenic index as a marker of pancreatic β-cell function. All patients underwent an oral glucose tolerance test, and 57 underwent an IVGTT for the calculation of first-phase (FPIR) and acute insulin responses (AIR). RESULTS: The F508del homozygous patients had an increased chance of developing impaired glucose tolerance (IGT) and significantly lower FPIR, decreased HOMA-IR, and insulinogenic index. Heterozygote F508del patients had an increased chance of having normal glucose tolerance. HOMA-IR, FGIR, and insulinogenic index did not change with age or clinical score. HOMAIR correlated with FPIR. FPIR correlated positively with insulinogenic index. AIR correlated negatively with FGIR, and positively with C-reactive protein. In multiple linear regression analyses, glucose tolerance was related to the agegroup, and to the HOMA-IR and insulinogenic indexes. CONCLUSIONS: IGT and CFRD were related mainly to genotype, although, as expected, the prevalence increased with age. The data suggested a possible combined contribution of insulin deficiency, β-cell function, and reduced insulin sensitivity to the onset of CFRD; however, further studies are warranted to better elucidate this aspect.
Authors: Gabriel I Uwaifo; Erica M Fallon; Jeff Chin; Jane Elberg; Shamik J Parikh; Jack A Yanovski Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112
Authors: F Lombardo; F De Luca; M Rosano; C Sferlazzas; C Lucanto; T Arrigo; M F Messina; G Crisafulli; M Wasniewska; M Valenzise; D Cucinotta Journal: Eur J Endocrinol Date: 2003-07 Impact factor: 6.664
Authors: Xingshen Sun; Yaling Yi; Bo Liang; Yu Yang; Nan He; Katie Larson Ode; Aliye Uc; Kai Wang; Katherine N Gibson-Corley; John F Engelhardt; Andrew W Norris Journal: J Cyst Fibros Date: 2019-02-07 Impact factor: 5.482
Authors: Michael G White; Rashmi R Maheshwari; Scott J Anderson; Rolando Berlinguer-Palmini; Claire Jones; Sarah J Richardson; Pavana G Rotti; Sarah L Armour; Yuchun Ding; Natalio Krasnogor; John F Engelhardt; Mike A Gray; Noel G Morgan; James A M Shaw Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958
Authors: Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt Journal: J Clin Invest Date: 2012-09-17 Impact factor: 14.808
Authors: Yaling Yi; Xingshen Sun; Katherine Gibson-Corley; Weiliang Xie; Bo Liang; Nan He; Scott R Tyler; Aliye Uc; Louis H Philipson; Kai Wang; Manami Hara; Katie Larson Ode; Andrew W Norris; John F Engelhardt Journal: Endocrinology Date: 2016-02-10 Impact factor: 4.736
Authors: Xingshen Sun; Yaling Yi; Weiliang Xie; Bo Liang; Michael C Winter; Nan He; Xiaoming Liu; Meihui Luo; Yu Yang; Katie Larson Ode; Aliye Uc; Andrew W Norris; John F Engelhardt Journal: Endocrinology Date: 2017-10-01 Impact factor: 4.736
Authors: Arianna Smerieri; Luisa Montanini; Luigi Maiuri; Sergio Bernasconi; Maria E Street Journal: Int J Mol Sci Date: 2014-10-08 Impact factor: 5.923